|

TriMaximize: A Multicentre, Prospective, Non-interventional Trial in Asthma Patients

RECRUITINGSponsored by Chiesi Poland Sp. z o.o.
Actively Recruiting
SponsorChiesi Poland Sp. z o.o.
Started2024-08
Est. completion2025-03-01
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06567977

Summary

TriMaximize: A multicentre, prospective, non-interventional trial monitoring therapy pathways of asthma patients treated with an extra-fine ICS/LABA/LAMA single-inhaler triple therapy in a real-world setting and characterizing the effects on health-related outcomes.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Patients ≥ 18 years of age,
* Patients with confirmed leading diagnosis of asthma with or without concomitant COPD,
* Physician decision to start fixed triple therapy with ICS/LABA/LAMA (Trimbow® MS or HS) according to its current authorised indication. The treatment decision must be made independently from participation in this NIS,
* Patients willing and able to sign an informed consent for use of their pseudonymised clinical data within the present non-interventional study.

Exclusion Criteria:

• Participation in an interventional clinical trial within 30 days prior to en-rolment into the present non-interventional study or planned enrolment in an interventional clinical trial during the observational period.

Conditions1

Asthma

Browse More Trials

Asthma trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.